Northwest Biotherapeutics reported $76.14M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Celldex Therapeutics USD 721.53M 60.82M Sep/2026
Eisai JPY 1.52T 33.49B Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Northwest Biotherapeutics USD 76.14M 3.91M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Plus Therapeutics USD 14.03M 5.89M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026